生物製剤の同一性試験世界市場の見通し：詳細分析、予測(～2031年)

当レポートは、生物製剤の同一性試験 (Biologics Identity Testing) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 調査対象

• 概要 生物製剤の同一性試験: 定義、特性、主要属性
• 市場セグメント：タイプ別
  • 世界の生物製剤の同一性試験 市場規模：タイプ別, 2020 VS 2024 VS 2031
  • Method Development and Validation
  • Commercial Support Services
  • Others
• 市場セグメント：アプリケーション別
  • 世界の生物製剤の同一性試験 市場規模：用途別, 2020 VS 2024 VS 2031
  • Innovative Biologics Development
  • Biologics Development
  • Academic and Research Institutions
  • Others
• 前提条件と制限
• 調査目的
• 対象期間

第2章 レポート概要

• 世界の生物製剤の同一性試験の収益 推定および予測 2020-2031
• 世界の生物製剤の同一性試験 収益：地域別
  • 収益比較: 2020 VS 2024 VS 2031
  • 収益実績と予測 地域別 (2020-2031)
  • 世界の収益市場シェア 地域別 (2020-2031)
  • 新興市場: 成長要因と投資動向

第3章 企業間の競争

• 世界の生物製剤の同一性試験 企業の収益ランキングと収益性
  • 世界の収益 (価格) ：競合別 (2020-2025)
  • 世界の主要企業の収益ランキング (2023 vs. 2024)
  • 収益ベースのTierセグメンテーション (Tier 1, Tier 2, and Tier 3)
  • 売上高総利益：トップ企業別 (2020 VS 2024)
• 世界の生物製剤の同一性試験 企業本社とサービス拠点
• 主要製品タイプ 市場規模：企業別
  • Method Development and Validation Market Size by Players
  • Commercial Support Services Market Size by Players
  • Others Market Size by Players
• 世界の生物製剤の同一性試験 市場集中と力学
  • 世界の市場集中 (CR5 and HHI)
  • 新規参入／イグジットの影響分析
  • 戦略的な動き: M&A、事業拡大, 研究開発投資

第4章 世界の製品セグメンテーション分析

• 世界の生物製剤の同一性試験 収益動向 タイプ別
  • 世界の収益実績と予測 タイプ別 (2020-2031)
  • 世界の収益市場シェア：タイプ別 (2020-2031)
• 主要製品の属性と差別化
• サブタイプの力学: 成長リーダー、収益性、リスク
  • 高成長な特定分野と採用ドライバー
  • 収益ホットスポットとコストドライバー
  • 代替品の脅威

第5章 世界の下流アプリケーション分析

• 世界の生物製剤の同一性試験 収益：用途別
  • 世界の実績al andの収益予測：用途別 (2020-2031)
  • の収益市場シェア：用途別 (2020-2031)
  • 高成長アプリケーション識別
  • 新興アプリケーションのケーススタディ
• 下流 顧客分析
  • トップ顧客 地域別
  • トップ顧客 用途別

第6章 北米

• 北米の市場規模 (2020-2031)
• 北米の主要企業 収益 2024年
• 北米の生物製剤の同一性試験 市場規模：タイプ別 (2020-2031)
• 北米の生物製剤の同一性試験 市場規模：用途別 (2020-2031)
• 北米の成長促進要因と市場障壁
• 北米の生物製剤の同一性試験 市場規模：国別
  • 北米の収益動向：国別
  • US
  • カナダ
  • メキシコ

第7章 欧州

• 欧州の市場規模 (2020-2031)
• 欧州の主要企業 収益 2024年
• 欧州の生物製剤の同一性試験 市場規模：タイプ別 (2020-2031)
• 欧州の生物製剤の同一性試験 市場規模：用途別 (2020-2031)
• 欧州の成長促進要因と市場障壁
• 欧州の生物製剤の同一性試験 市場規模：国別
  • 欧州の収益動向：国別
  • ドイツ
  • フランス
  • 英国
  • イタリア
  • ロシア

第8章 アジア太平洋地域

• アジア太平洋地域 市場規模 (2020-2031)
• アジア太平洋地域 主要企業 収益 2024年
• アジア太平洋地域 生物製剤の同一性試験 市場規模：タイプ別 (2020-2031)
• アジア太平洋地域 生物製剤の同一性試験 市場規模：用途別 (2020-2031)
• アジア太平洋地域 成長促進要因と市場障壁
• アジア太平洋地域 生物製剤の同一性試験 市場規模：地域別
  • アジア太平洋地域 収益動向 地域別
• 中国
• 日本
• 韓国
• オーストラリア
• インド
• 東南アジア
  • インドネシア
  • ベトナム
  • マレーシア
  • フィリピン
  • シンガポール

第9章 中南米

• 中南米 市場規模 (2020-2031)
• 中南米 主要企業 収益 2024年
• 中南米 生物製剤の同一性試験 市場規模：タイプ別 (2020-2031)
• 中南米 生物製剤の同一性試験 市場規模：用途別 (2020-2031)
• 中南米 投資機会と主な課題
• 中南米 生物製剤の同一性試験 市場規模：国別
  • 中南米 収益動向：国別 (2020 VS 2024 VS 2031)
  • ブラジル
  • アルゼンチン

第10章 中東・アフリカ

• 中東・アフリカの市場規模 (2020-2031)
• 中東・アフリカの主要企業 収益 2024年
• 中東・アフリカの生物製剤の同一性試験 市場規模：タイプ別 (2020-2031)
• 中東・アフリカの生物製剤の同一性試験 市場規模：用途別 (2020-2031)
• 中東・アフリカの投資機会と主な課題
• 中東・アフリカの生物製剤の同一性試験 市場規模：国別
  • 中東・アフリカの収益動向：国別 (2020 VS 2024 VS 2031)
  • 湾岸協力理事会諸国
  • イスラエル
  • エジプト
  • 南アフリカ

第11章 企業プロファイル

• Clean Cells
• Charles River Laboratories
• SGS SA
• Eurofins Scientific
• BioAgilytix Labs
• Genscript Biotech Corp.
• AbbVie Inc.
• Rentschler Biopharma SE
• Syngene International Ltd.
• Thermo Fisher Scientific Inc.
• GL Biochem Corp.
• Abzena plc

第12章 生物製剤の同一性試験業界チェーン分析

• 生物製剤の同一性試験 産業チェーン
• 上流分析
  • 上流 主要サプライヤー
• 中流分析
• 下流 販売モデルと流通ネットワーク
  • 販売チャネル
  • 卸業者

第13章 生物製剤の同一性試験 市場動向

• 業界動向と進化
• 市場 成長ドライバーと新興の機会
• 市場の課題、リスク、抑制

第14章 主な調査結果 世界の生物製剤の同一性試験の主な市場調査結果

第15章 付録

List of Tables

Table 1. Global Biologics Identity Testing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Table 2. Global Biologics Identity Testing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Table 3. Global Biologics Identity Testing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 4. Global Biologics Identity Testing Revenue by Region (2020-2025) & (US$ Million)

Table 5. Global Biologics Identity Testing Revenue by Region (2026-2031) & (US$ Million)

Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 7. Global Biologics Identity Testing Revenue by Players (2020-2025) & (US$ Million)

Table 8. Global Biologics Identity Testing Revenue Market Share by Players (2020-2025)

Table 9. Global Key Players'Ranking Shift (2023 vs. 2024) (Based on Revenue)

Table 10. Global Biologics Identity Testing by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Biologics Identity Testing as of 2024)

Table 11. Global Biologics Identity Testing Average Gross Margin (%) by Player (2020 VS 2024)

Table 12. Global Biologics Identity Testing Companies Headquarters

Table 13. Global Biologics Identity Testing Market Concentration Ratio (CR5 and HHI)

Table 14. Key Market Entrant/Exit (2020-2024) - Drivers & Impact Analysis

Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment

Table 16. Global Biologics Identity Testing Revenue by Type (2020-2025) & (US$ Million)

Table 17. Global Biologics Identity Testing Revenue by Type (2026-2031) & (US$ Million)

Table 18. Key Product Attributes and Differentiation

Table 19. Global Biologics Identity Testing Revenue by Application (2020-2025) & (US$ Million)

Table 20. Global Biologics Identity Testing Revenue by Application (2026-2031) & (US$ Million)

Table 21. Biologics Identity Testing High-Growth Sectors Demand CAGR (2024-2031)

Table 22. Top Customers by Region

Table 23. Top Customers by Application

Table 24. North America Biologics Identity Testing Growth Accelerators and Market Barriers

Table 25. North America Biologics Identity Testing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 26. Europe Biologics Identity Testing Growth Accelerators and Market Barriers

Table 27. Europe Biologics Identity Testing Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 28. Asia-Pacific Biologics Identity Testing Growth Accelerators and Market Barriers

Table 29. Asia-Pacific Biologics Identity Testing Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 30. Central and South America Biologics Identity Testing Investment Opportunities and Key Challenges

Table 31. Central and South America Biologics Identity Testing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 32. Middle East and Africa Biologics Identity Testing Investment Opportunities and Key Challenges

Table 33. Middle East and Africa Biologics Identity Testing Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)

Table 34. Clean Cells Corporation Information

Table 35. Clean Cells Description and Major Businesses

Table 36. Clean Cells Product Features and Attributes

Table 37. Clean Cells Revenue (US$ Million) and Gross Margin (2020-2025)

Table 38. Clean Cells Revenue Proportion by Product in 2024

Table 39. Clean Cells Revenue Proportion by Application in 2024

Table 40. Clean Cells Revenue Proportion by Geographic Area in 2024

Table 41. Clean Cells Biologics Identity Testing SWOT Analysis

Table 42. Clean Cells Recent Developments

Table 43. Charles River Laboratories Corporation Information

Table 44. Charles River Laboratories Description and Major Businesses

Table 45. Charles River Laboratories Product Features and Attributes

Table 46. Charles River Laboratories Revenue (US$ Million) and Gross Margin (2020-2025)

Table 47. Charles River Laboratories Revenue Proportion by Product in 2024

Table 48. Charles River Laboratories Revenue Proportion by Application in 2024

Table 49. Charles River Laboratories Revenue Proportion by Geographic Area in 2024

Table 50. Charles River Laboratories Biologics Identity Testing SWOT Analysis

Table 51. Charles River Laboratories Recent Developments

Table 52. SGS SA Corporation Information

Table 53. SGS SA Description and Major Businesses

Table 54. SGS SA Product Features and Attributes

Table 55. SGS SA Revenue (US$ Million) and Gross Margin (2020-2025)

Table 56. SGS SA Revenue Proportion by Product in 2024

Table 57. SGS SA Revenue Proportion by Application in 2024

Table 58. SGS SA Revenue Proportion by Geographic Area in 2024

Table 59. SGS SA Biologics Identity Testing SWOT Analysis

Table 60. SGS SA Recent Developments

Table 61. Eurofins Scientific Corporation Information

Table 62. Eurofins Scientific Description and Major Businesses

Table 63. Eurofins Scientific Product Features and Attributes

Table 64. Eurofins Scientific Revenue (US$ Million) and Gross Margin (2020-2025)

Table 65. Eurofins Scientific Revenue Proportion by Product in 2024

Table 66. Eurofins Scientific Revenue Proportion by Application in 2024

Table 67. Eurofins Scientific Revenue Proportion by Geographic Area in 2024

Table 68. Eurofins Scientific Biologics Identity Testing SWOT Analysis

Table 69. Eurofins Scientific Recent Developments

Table 70. BioAgilytix Labs Corporation Information

Table 71. BioAgilytix Labs Description and Major Businesses

Table 72. BioAgilytix Labs Product Features and Attributes

Table 73. BioAgilytix Labs Revenue (US$ Million) and Gross Margin (2020-2025)

Table 74. BioAgilytix Labs Revenue Proportion by Product in 2024

Table 75. BioAgilytix Labs Revenue Proportion by Application in 2024

Table 76. BioAgilytix Labs Revenue Proportion by Geographic Area in 2024

Table 77. BioAgilytix Labs Biologics Identity Testing SWOT Analysis

Table 78. BioAgilytix Labs Recent Developments

Table 79. Genscript Biotech Corp. Corporation Information

Table 80. Genscript Biotech Corp. Description and Major Businesses

Table 81. Genscript Biotech Corp. Product Features and Attributes

Table 82. Genscript Biotech Corp. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 83. Genscript Biotech Corp. Recent Developments

Table 84. AbbVie Inc. Corporation Information

Table 85. AbbVie Inc. Description and Major Businesses

Table 86. AbbVie Inc. Product Features and Attributes

Table 87. AbbVie Inc. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 88. AbbVie Inc. Recent Developments

Table 89. Rentschler Biopharma SE Corporation Information

Table 90. Rentschler Biopharma SE Description and Major Businesses

Table 91. Rentschler Biopharma SE Product Features and Attributes

Table 92. Rentschler Biopharma SE Revenue (US$ Million) and Gross Margin (2020-2025)

Table 93. Rentschler Biopharma SE Recent Developments

Table 94. Syngene International Ltd. Corporation Information

Table 95. Syngene International Ltd. Description and Major Businesses

Table 96. Syngene International Ltd. Product Features and Attributes

Table 97. Syngene International Ltd. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 98. Syngene International Ltd. Recent Developments

Table 99. Thermo Fisher Scientific Inc. Corporation Information

Table 100. Thermo Fisher Scientific Inc. Description and Major Businesses

Table 101. Thermo Fisher Scientific Inc. Product Features and Attributes

Table 102. Thermo Fisher Scientific Inc. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 103. Thermo Fisher Scientific Inc. Recent Developments

Table 104. GL Biochem Corp. Corporation Information

Table 105. GL Biochem Corp. Description and Major Businesses

Table 106. GL Biochem Corp. Product Features and Attributes

Table 107. GL Biochem Corp. Revenue (US$ Million) and Gross Margin (2020-2025)

Table 108. GL Biochem Corp. Recent Developments

Table 109. Abzena plc Corporation Information

Table 110. Abzena plc Description and Major Businesses

Table 111. Abzena plc Product Features and Attributes

Table 112. Abzena plc Revenue (US$ Million) and Gross Margin (2020-2025)

Table 113. Abzena plc Recent Developments

Table 114. Raw Materials Key Suppliers

Table 115. Distributors List

Table 116. Market Trends and Market Evolution

Table 117. Market Drivers and Opportunities

Table 118. Market Challenges, Risks, and Restraints

Table 119. Research Programs/Design for This Report

Table 120. Key Data Information from Secondary Sources

Table 121. Key Data Information from Primary Sources

List of Figures

Figure 1. Biologics Identity Testing Product Picture

Figure 2. Global Biologics Identity Testing Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)

Figure 3. Method Development and Validation Product Picture

Figure 4. Commercial Support Services Product Picture

Figure 5. Others Product Picture

Figure 6. Global Biologics Identity Testing Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)

Figure 7. Innovative Biologics Development

Figure 8. Biologics Development

Figure 9. Academic and Research Institutions

Figure 10. Others

Figure 11. Biologics Identity Testing Report Years Considered

Figure 12. Global Biologics Identity Testing Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 14. Global Biologics Identity Testing Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)

Figure 15. Global Biologics Identity Testing Revenue Market Share by Region (2020-2031)

Figure 16. Global Biologics Identity Testing Revenue Market Share Ranking (2024)

Figure 17. Tier Distribution by Revenue Contribution (2020 VS 2024)

Figure 18. Method Development and Validation Revenue Market Share by Player in 2024

Figure 19. Commercial Support Services Revenue Market Share by Player in 2024

Figure 20. Others Revenue Market Share by Player in 2024

Figure 21. Global Biologics Identity Testing Revenue Market Share by Type (2020-2031)

Figure 22. Global Biologics Identity Testing Revenue Market Share by Application (2020-2031)

Figure 23. North America Biologics Identity Testing Revenue YoY (2020-2031) & (US$ Million)

Figure 24. North America Top 5 Players Biologics Identity Testing Revenue (US$ Million) in 2024

Figure 25. North America Biologics Identity Testing Revenue (US$ Million) by Type (2020 - 2031)

Figure 26. North America Biologics Identity Testing Revenue (US$ Million) by Application (2020-2031)

Figure 27. US Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 28. Canada Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 29. Mexico Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 30. Europe Biologics Identity Testing Revenue YoY (2020-2031) & (US$ Million)

Figure 31. Europe Top 5 Players Biologics Identity Testing Revenue (US$ Million) in 2024

Figure 32. Europe Biologics Identity Testing Revenue (US$ Million) by Type (2020-2031)

Figure 33. Europe Biologics Identity Testing Revenue (US$ Million) by Application (2020-2031)

Figure 34. Germany Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 35. France Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 36. U.K. Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 37. Italy Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 38. Russia Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 39. Asia-Pacific Biologics Identity Testing Revenue YoY (2020-2031) & (US$ Million)

Figure 40. Asia-Pacific Top 8 Players Biologics Identity Testing Revenue (US$ Million) in 2024

Figure 41. Asia-Pacific Biologics Identity Testing Revenue (US$ Million) by Type (2020-2031)

Figure 42. Asia-Pacific Biologics Identity Testing Revenue (US$ Million) by Application (2020-2031)

Figure 43. Indonesia Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 44. Japan Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 45. South Korea Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 46. Australia Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 47. India Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 48. Indonesia Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 49. Vietnam Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 50. Malaysia Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 51. Philippines Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 52. Singapore Biologics Identity Testing Revenue (2020-2031) & (US$ Million)

Figure 53. Central and South America Biologics Identity Testing Revenue YoY (2020-2031) & (US$ Million)

Figure 54. Central and South America Top 5 Players Biologics Identity Testing Revenue (US$ Million) in 2024

Figure 55. Central and South America Biologics Identity Testing Revenue (US$ Million) by Type (2020-2031)

Figure 56. Central and South America Biologics Identity Testing Revenue (US$ Million) by Application (2020-2031)

Figure 57. Brazil Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 58. Argentina Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 59. Middle East and Africa Biologics Identity Testing Revenue YoY (2020-2031) & (US$ Million)

Figure 60. Middle East and Africa Top 5 Players Biologics Identity Testing Revenue (US$ Million) in 2024

Figure 61. South America Biologics Identity Testing Revenue (US$ Million) by Type (2020-2031)

Figure 62. Middle East and Africa Biologics Identity Testing Revenue (US$ Million) by Application (2020-2031)

Figure 63. GCC Countries Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 64. Israel Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 65. Egypt Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 66. South Africa Biologics Identity Testing Revenue (2020-2025) & (US$ Million)

Figure 67. Biologics Identity Testing Industry Chain Mapping

Figure 68. Channels of Distribution (Direct Vs Distribution)

Figure 69. Bottom-up and Top-down Approaches for This Report

Figure 70. Data Triangulation

Figure 71. Key Executives Interviewed

This research report focuses on the Biologics Identity Testing Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Study Coverage

• 1.1 Introduction to Biologics Identity Testing: Definition, Properties, and Key Attributes
• 1.2 Market Segmentation by Type
  • 1.2.1 Global Biologics Identity Testing Market Size by Type, 2020 VS 2024 VS 2031
  • 1.2.2 Method Development and Validation
  • 1.2.3 Commercial Support Services
  • 1.2.4 Others
• 1.3 Market Segmentation by Application
  • 1.3.1 Global Biologics Identity Testing Market Size by Application, 2020 VS 2024 VS 2031
  • 1.3.2 Innovative Biologics Development
  • 1.3.3 Biologics Development
  • 1.3.4 Academic and Research Institutions
  • 1.3.5 Others
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Executive Summary

• 2.1 Global Biologics Identity Testing Revenue Estimates and Forecasts 2020-2031
• 2.2 Global Biologics Identity Testing Revenue by Region
  • 2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
  • 2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
  • 2.2.3 Global Revenue Market Share by Region (2020-2031)
  • 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competition by Players

• 3.1 Global Biologics Identity Testing Player Revenue Rankings and Profitability
  • 3.1.1 Global Revenue (Value) by Players (2020-2025)
  • 3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
  • 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
  • 3.1.4 Gross Margin by Top Player (2020 VS 2024)
• 3.2 Global Biologics Identity Testing Companies Headquarters and Service Footprint
• 3.3 Main Product Type Market Size by Players
  • 3.3.1 Method Development and Validation Market Size by Players
  • 3.3.2 Commercial Support Services Market Size by Players
  • 3.3.3 Others Market Size by Players
• 3.4 Global Biologics Identity Testing Market Concentration and Dynamics
  • 3.4.1 Global Market Concentration (CR5 and HHI)
  • 3.4.2 Entrant/Exit Impact Analysis
  • 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Global Product Segmentation Analysis

• 4.1 Global Biologics Identity Testing Revenue Trends by Type
  • 4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
  • 4.1.2 Global Revenue Market Share by Type (2020-2031)
• 4.2 Key Product Attributes and Differentiation
• 4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
  • 4.3.1 High-Growth Niches and Adoption Drivers
  • 4.3.2 Profitability Hotspots and Cost Drivers
  • 4.3.3 Substitution Threats

5 Global Downstream Application Analysis

• 5.1 Global Biologics Identity Testing Revenue by Application
  • 5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
  • 5.1.2 Revenue Market Share by Application (2020-2031)
  • 5.1.3 High-Growth Application Identification
  • 5.1.4 Emerging Application Case Studies
• 5.2 Downstream Customer Analysis
  • 5.2.1 Top Customers by Region
  • 5.2.2 Top Customers by Application

6 North America

• 6.1 North America Market Size (2020-2031)
• 6.2 North America Key Players Revenue in 2024
• 6.3 North America Biologics Identity Testing Market Size by Type (2020-2031)
• 6.4 North America Biologics Identity Testing Market Size by Application (2020-2031)
• 6.5 North America Growth Accelerators and Market Barriers
• 6.6 North America Biologics Identity Testing Market Size by Country
  • 6.6.1 North America Revenue Trends by Country
  • 6.6.2 US
  • 6.6.3 Canada
  • 6.6.4 Mexico

7 Europe

• 7.1 Europe Market Size (2020-2031)
• 7.2 Europe Key Players Revenue in 2024
• 7.3 Europe Biologics Identity Testing Market Size by Type (2020-2031)
• 7.4 Europe Biologics Identity Testing Market Size by Application (2020-2031)
• 7.5 Europe Growth Accelerators and Market Barriers
• 7.6 Europe Biologics Identity Testing Market Size by Country
  • 7.6.1 Europe Revenue Trends by Country
  • 7.6.2 Germany
  • 7.6.3 France
  • 7.6.4 U.K.
  • 7.6.5 Italy
  • 7.6.6 Russia

8 Asia-Pacific

• 8.1 Asia-Pacific Market Size (2020-2031)
• 8.2 Asia-Pacific Key Players Revenue in 2024
• 8.3 Asia-Pacific Biologics Identity Testing Market Size by Type (2020-2031)
• 8.4 Asia-Pacific Biologics Identity Testing Market Size by Application (2020-2031)
• 8.5 Asia-Pacific Growth Accelerators and Market Barriers
• 8.6 Asia-Pacific Biologics Identity Testing Market Size by Region
  • 8.6.1 Asia-Pacific Revenue Trends by Region
• 8.7 China
• 8.8 Japan
• 8.9 South Korea
• 8.10 Australia
• 8.11 India
• 8.12 Southeast Asia
  • 8.12.1 Indonesia
  • 8.12.2 Vietnam
  • 8.12.3 Malaysia
  • 8.12.4 Philippines
  • 8.12.5 Singapore

9 Central and South America

• 9.1 Central and South America Market Size (2020-2031)
• 9.2 Central and South America Key Players Revenue in 2024
• 9.3 Central and South America Biologics Identity Testing Market Size by Type (2020-2031)
• 9.4 Central and South America Biologics Identity Testing Market Size by Application (2020-2031)
• 9.5 Central and South America Investment Opportunities and Key Challenges
• 9.6 Central and South America Biologics Identity Testing Market Size by Country
  • 9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 9.6.2 Brazil
  • 9.6.3 Argentina

10 Middle East and Africa

• 10.1 Middle East and Africa Market Size (2020-2031)
• 10.2 Middle East and Africa Key Players Revenue in 2024
• 10.3 Middle East and Africa Biologics Identity Testing Market Size by Type (2020-2031)
• 10.4 Middle East and Africa Biologics Identity Testing Market Size by Application (2020-2031)
• 10.5 Middle East and Africa Investment Opportunities and Key Challenges
• 10.6 Middle East and Africa Biologics Identity Testing Market Size by Country
  • 10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
  • 10.6.2 GCC Countries
  • 10.6.3 Israel
  • 10.6.4 Egypt
  • 10.6.5 South Africa

11 Corporate Profile

• 11.1 Clean Cells
  • 11.1.1 Clean Cells Corporation Information
  • 11.1.2 Clean Cells Business Overview
  • 11.1.3 Clean Cells Biologics Identity Testing Product Features and Attributes
  • 11.1.4 Clean Cells Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.1.5 Clean Cells Biologics Identity Testing Revenue by Product in 2024
  • 11.1.6 Clean Cells Biologics Identity Testing Revenue by Application in 2024
  • 11.1.7 Clean Cells Biologics Identity Testing Revenue by Geographic Area in 2024
  • 11.1.8 Clean Cells Biologics Identity Testing SWOT Analysis
  • 11.1.9 Clean Cells Recent Developments
• 11.2 Charles River Laboratories
  • 11.2.1 Charles River Laboratories Corporation Information
  • 11.2.2 Charles River Laboratories Business Overview
  • 11.2.3 Charles River Laboratories Biologics Identity Testing Product Features and Attributes
  • 11.2.4 Charles River Laboratories Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.2.5 Charles River Laboratories Biologics Identity Testing Revenue by Product in 2024
  • 11.2.6 Charles River Laboratories Biologics Identity Testing Revenue by Application in 2024
  • 11.2.7 Charles River Laboratories Biologics Identity Testing Revenue by Geographic Area in 2024
  • 11.2.8 Charles River Laboratories Biologics Identity Testing SWOT Analysis
  • 11.2.9 Charles River Laboratories Recent Developments
• 11.3 SGS SA
  • 11.3.1 SGS SA Corporation Information
  • 11.3.2 SGS SA Business Overview
  • 11.3.3 SGS SA Biologics Identity Testing Product Features and Attributes
  • 11.3.4 SGS SA Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.3.5 SGS SA Biologics Identity Testing Revenue by Product in 2024
  • 11.3.6 SGS SA Biologics Identity Testing Revenue by Application in 2024
  • 11.3.7 SGS SA Biologics Identity Testing Revenue by Geographic Area in 2024
  • 11.3.8 SGS SA Biologics Identity Testing SWOT Analysis
  • 11.3.9 SGS SA Recent Developments
• 11.4 Eurofins Scientific
  • 11.4.1 Eurofins Scientific Corporation Information
  • 11.4.2 Eurofins Scientific Business Overview
  • 11.4.3 Eurofins Scientific Biologics Identity Testing Product Features and Attributes
  • 11.4.4 Eurofins Scientific Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.4.5 Eurofins Scientific Biologics Identity Testing Revenue by Product in 2024
  • 11.4.6 Eurofins Scientific Biologics Identity Testing Revenue by Application in 2024
  • 11.4.7 Eurofins Scientific Biologics Identity Testing Revenue by Geographic Area in 2024
  • 11.4.8 Eurofins Scientific Biologics Identity Testing SWOT Analysis
  • 11.4.9 Eurofins Scientific Recent Developments
• 11.5 BioAgilytix Labs
  • 11.5.1 BioAgilytix Labs Corporation Information
  • 11.5.2 BioAgilytix Labs Business Overview
  • 11.5.3 BioAgilytix Labs Biologics Identity Testing Product Features and Attributes
  • 11.5.4 BioAgilytix Labs Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.5.5 BioAgilytix Labs Biologics Identity Testing Revenue by Product in 2024
  • 11.5.6 BioAgilytix Labs Biologics Identity Testing Revenue by Application in 2024
  • 11.5.7 BioAgilytix Labs Biologics Identity Testing Revenue by Geographic Area in 2024
  • 11.5.8 BioAgilytix Labs Biologics Identity Testing SWOT Analysis
  • 11.5.9 BioAgilytix Labs Recent Developments
• 11.6 Genscript Biotech Corp.
  • 11.6.1 Genscript Biotech Corp. Corporation Information
  • 11.6.2 Genscript Biotech Corp. Business Overview
  • 11.6.3 Genscript Biotech Corp. Biologics Identity Testing Product Features and Attributes
  • 11.6.4 Genscript Biotech Corp. Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.6.5 Genscript Biotech Corp. Recent Developments
• 11.7 AbbVie Inc.
  • 11.7.1 AbbVie Inc. Corporation Information
  • 11.7.2 AbbVie Inc. Business Overview
  • 11.7.3 AbbVie Inc. Biologics Identity Testing Product Features and Attributes
  • 11.7.4 AbbVie Inc. Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.7.5 AbbVie Inc. Recent Developments
• 11.8 Rentschler Biopharma SE
  • 11.8.1 Rentschler Biopharma SE Corporation Information
  • 11.8.2 Rentschler Biopharma SE Business Overview
  • 11.8.3 Rentschler Biopharma SE Biologics Identity Testing Product Features and Attributes
  • 11.8.4 Rentschler Biopharma SE Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.8.5 Rentschler Biopharma SE Recent Developments
• 11.9 Syngene International Ltd.
  • 11.9.1 Syngene International Ltd. Corporation Information
  • 11.9.2 Syngene International Ltd. Business Overview
  • 11.9.3 Syngene International Ltd. Biologics Identity Testing Product Features and Attributes
  • 11.9.4 Syngene International Ltd. Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.9.5 Syngene International Ltd. Recent Developments
• 11.10 Thermo Fisher Scientific Inc.
  • 11.10.1 Thermo Fisher Scientific Inc. Corporation Information
  • 11.10.2 Thermo Fisher Scientific Inc. Business Overview
  • 11.10.3 Thermo Fisher Scientific Inc. Biologics Identity Testing Product Features and Attributes
  • 11.10.4 Thermo Fisher Scientific Inc. Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.10.5 Company Ten Recent Developments
• 11.11 GL Biochem Corp.
  • 11.11.1 GL Biochem Corp. Corporation Information
  • 11.11.2 GL Biochem Corp. Business Overview
  • 11.11.3 GL Biochem Corp. Biologics Identity Testing Product Features and Attributes
  • 11.11.4 GL Biochem Corp. Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.11.5 GL Biochem Corp. Recent Developments
• 11.12 Abzena plc
  • 11.12.1 Abzena plc Corporation Information
  • 11.12.2 Abzena plc Business Overview
  • 11.12.3 Abzena plc Biologics Identity Testing Product Features and Attributes
  • 11.12.4 Abzena plc Biologics Identity Testing Revenue and Gross Margin (2020-2025)
  • 11.12.5 Abzena plc Recent Developments

12 Biologics Identity TestingIndustry Chain Analysis

• 12.1 Biologics Identity Testing Industry Chain
• 12.2 Upstream Analysis
  • 12.2.1 Upstream Key Suppliers
• 12.3 Middlestream Analysis
• 12.4 Downstream Sales Model and Distribution Networks
  • 12.4.1 Sales Channels
  • 12.4.2 Distributors

13 Biologics Identity Testing Market Dynamics

• 13.1 Industry Trends and Evolution
• 13.2 Market Growth Drivers and Emerging Opportunities
• 13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Biologics Identity Testing Study

15 Appendix

• 15.1 Research Methodology
  • 15.1.1 Methodology/Research Approach
    • 15.1.1.1 Research Programs/Design
    • 15.1.1.2 Market Size Estimation
    • 15.1.1.3 Market Breakdown and Data Triangulation
  • 15.1.2 Data Source
    • 15.1.2.1 Secondary Sources
    • 15.1.2.2 Primary Sources
• 15.2 Author Details